The nation of Zimbabwe has rejected a significant US health deal valued at $367m (£272m) over five years because of the United States' request for confidential information.
The decision became public after a official document from December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "skewed".
An official representative has since explained that the United States was demanding access to genetic material for research and commercial purposes but was not willing to share the benefits from any future treatments.
"We must now begin the difficult and regrettable task of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for continued negotiations to secure a deal agreeable to both sides so the nation's vital HIV programme can proceed.
Broader Background
This development follows a similar case in Kenya, where a court halted a similar health funding agreement following concerns were filed about the security of citizens' health data.
After returning to office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government agreements to boost transparency and responsibility.
Based on reports, Sixteen nations in Africa have to date agreed to similar agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to provide its biological resources and data over an extended period, with no corresponding assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," he stated.
"Put simply, our nation would supply the basic resources for scientific discovery with no assurance that the resulting innovations would be available to our people should a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending frameworks already established via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This framework is intended to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how subsequent collaboration might be designed in a manner that respects the sovereignty and interests of both nations."
Medical Community Response
A leading public health body stated it acknowledged the official position, but urged that talks should continue considering much of the country's Aids initiatives were funded by foreign aid.
"If technical issues exist, such as those relating to data governance or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group commented.
The situation emphasises the ongoing debate between receiving much-needed international aid and protecting national sovereignty in an ever more data-driven world.